All In Biotech

Free tool

FAERS Monitor: Ojemda

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 218033 or its brand name (Ojemda, Tovorafenib). Reports on generic versions are filed under their own applications.

Reports

326

Serious

108

33% of reports

Hospitalization

41

Death reported

12

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use34
  • disease progression28
  • rash27
  • fatigue23
  • accidental underdose19
  • hair colour changes18
  • headache17
  • melanocytic naevus15
  • growth retardation12
  • blood creatine phosphokinase increased11
  • nausea11
  • acne10
  • dermatitis acneiform10
  • intracranial tumour haemorrhage10
  • photosensitivity reaction9

Reports by year received

View as table
YearReports
202469
2025179
202678

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,833 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
intracranial tumour haemorrhageSignal101713.1922.915,043
growth retardationSignal12264.1151.42,876
melanocytic naevusSignal15221.5135.03,066
dermatitis acneiformSignal10106.257.7938
hair colour changesSignal1893.559.61,554
accidental underdoseSignal1985.355.11,498
photosensitivity reactionSignal935.218.5266
blood creatine phosphokinase increasedSignal1124.713.8227
disease progressionSignal2815.310.7361
acneSignal108.54.659
rashSignal274.02.859
off label useSignal342.51.831
fatigue231.91.39
headache171.71.15
nausea110.90.50

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.